Improvements in patient-reported outcomes after neuromuscular electrical stimulation therapy for snoring and mild sleep apnea
- 1University of Strathclyde
Abstract
Objectives: Neuromuscular electrical stimulation (NMES) offers alternative options to patients with Obstructive Sleep Apnea (OSA) unable to tolerate first line treatment. Randomized controlled trial data suggest efficacy of NMES treatment in improving OSA outcomes, snoring and sleepiness; however, no study to our knowledge has examined the effects on a range of daytime patient reported outcomes in a large real-world sample. Methods: This report presents clinical data from 472 patients completing NMES treatment. Bayesian linear mixed models were used to analyze pre-to-post treatment changes in mood (PHQ8), sleep disturbance (PROMIS-SD-4a), sleep related impairment (PROMIS-SRI-4a), and functioning (FOSQ), whilst controlling for key covariates. Posterior probabilities were calculated to estimate the probability of a change in symptoms (P(effect > 0)) and probability of exceeding a minimal clinically important difference (P(effect > MCID)). Results: The posterior probabilities of an improvement in scores in sleep disturbance (mean change -6.1, 94% HDI: -3.8 to -8.5) and sleep-related impairment (mean change -10.0, 94% HDI: -5.4 to -14), depression (mean change -3.5, 94% HDI: -1.7 to -5.2), at posttreatment were greatest and varied between 99.8 to 100%. Probability of change in functioning was low (60.9% chance of improvement). These effects remained when controlling for age, gender, treatment adherence, mean intensity and variance in intensity. Probabilities for MCI change for mood, sleep disturbance and sleep-related impairment were high (86-91%). Conclusions: The results from this report highlight the potential impact NMES therapy has on patient reported outcomes. These findings are in support of prior randomized placebo-controlled data and several observational cohort studies for NMES as treatment for mild OSA.
Related
- Gait-triggered neuromuscular electrical stimulation as an adjunct to an offloading knee brace in medial knee osteoarthritis: a pilot randomized controlled trial
- Lower‐limb neuromuscular electrical stimulation (NMES) for adults with kidney failure undergoing dialysis
- Repeated Neuromuscular Electrical Stimulation Protocol Disrupts Muscle-to-Brain Signaling in Rats
- Isolated Patellar Chondromalacia Treated With Arthroscopic Chondroplasty Provides Significant Early Improvements in Patient‐Reported Outcomes
- Association between neuromuscular electrical stimulation and intermittent pneumatic compression for the prevention of deep venous thrombosis among neurosurgery patients
BibTeX
@misc{crawford2026improvements,
title = {{Improvements in patient-reported outcomes after neuromuscular electrical stimulation therapy for snoring and mild sleep apnea}},
author = {M. R. Crawford and A. L. Jones and S. Parthasarathy and C. Osborne and H. Walia and J. Ojile and A. Malhotra},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.02.26367068},
url = {https://www.medrxiv.org/content/10.64898/2026.11.02.26367068v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Improvements in patient-reported outcomes after neuromuscular electrical stimulation therapy for snoring and mild sleep apnea
AU - M. R. Crawford
AU - A. L. Jones
AU - S. Parthasarathy
AU - C. Osborne
AU - H. Walia
AU - J. Ojile
AU - A. Malhotra
PY - 2026
DA - 2026/11/02
PB - medRxiv
DO - 10.64898/2026.11.02.26367068
UR - https://www.medrxiv.org/content/10.64898/2026.11.02.26367068v1
AB - Objectives: Neuromuscular electrical stimulation (NMES) offers alternative options to patients with Obstructive Sleep Apnea (OSA) unable to tolerate first line treatment. Randomized controlled trial data suggest efficacy of NMES treatment in improving OSA outcomes, snoring and sleepiness; however, no study to our knowledge has examined the effects on a range of daytime patient reported outcomes in a large real-world sample. Methods: This report presents clinical data from 472 patients completing NMES treatment. Bayesian linear mixed models were used to analyze pre-to-post treatment changes in mood (PHQ8), sleep disturbance (PROMIS-SD-4a), sleep related impairment (PROMIS-SRI-4a), and functioning (FOSQ), whilst controlling for key covariates. Posterior probabilities were calculated to estimate the probability of a change in symptoms (P(effect > 0)) and probability of exceeding a minimal clinically important difference (P(effect > MCID)). Results: The posterior probabilities of an improvement in scores in sleep disturbance (mean change -6.1, 94% HDI: -3.8 to -8.5) and sleep-related impairment (mean change -10.0, 94% HDI: -5.4 to -14), depression (mean change -3.5, 94% HDI: -1.7 to -5.2), at posttreatment were greatest and varied between 99.8 to 100%. Probability of change in functioning was low (60.9% chance of improvement). These effects remained when controlling for age, gender, treatment adherence, mean intensity and variance in intensity. Probabilities for MCI change for mood, sleep disturbance and sleep-related impairment were high (86-91%). Conclusions: The results from this report highlight the potential impact NMES therapy has on patient reported outcomes. These findings are in support of prior randomized placebo-controlled data and several observational cohort studies for NMES as treatment for mild OSA.
ER -